James S. Minnion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James S. Minnion has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Tricia Tan
Department of Metabolism, Digestion and Reproduction Imperial College London London UK
11 shared publications - Stephen Robert Bloom
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
9 shared publications - Benjamin C. T. Field
Department of Diabetes and Endocrinology Surrey & Sussex Healthcare NHS Trust Redhill UK
6 shared publications - Kevin Graeme Murphy
Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK
6 shared publications Mohammad A. Ghatei
Section of Investigative Medicine (T.M.T., V.S., R.C.T., A.A., B.C.T.F., A.D.S., S.M., K.C.R.B., M.D., J.M., M.A.G., S.R.B.), London W12 0NN, United Kingdom
5 shared publications- Barbara McGowan
Department of Endocrinology and Diabetes, Guy’s & St Thomas’ Hospital NHS Trust, London, UK
3 shared publications
Latest Publications
- Open Access
- 5 October 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (1) , 65-77
Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists
Aim: Earlier studies have shown that peptide glucagon‐like peptide‐1 receptor (GLP‐1R) agonists with reduced β‐arrestin recruitment show enhanced anti‐hyperglycaemic efficacy through avoidance of GLP‐1R desensitization. However, the ligand modifications needed to decrease β‐arrestin recruitment usually also reduces GLP‐1R affinity, therefore higher doses are needed. Here we aimed to develop new, long‐acting, G protein‐biased GLP‐1R agonists with acute signalling potency comparable with semaglutide, to provide insights into specific experimental and therapeutic scenarios. Materials and Methods: New GLP‐1R agonist peptides were assessed using a variety of in vitro and in vivo assays. Results: First, we show that very substantial reductions in β‐arrestin recruitment efficacy are required to realize fully the benefits of GLP‐1R agonism on blood glucose lowering in mice, with more moderate reductions being less effective. Secondly, our lead compound (SRB107) performs substantially better than semaglutide for effects on blood glucose and weight loss, which may be jointly attributable to its biased agonist action and protracted pharmacokinetics. Thirdly, we show that biased agonist‐specific GLP‐1R internalization profiles occur at clinically relevant pharmacological concentrations. Finally, we show that SRB107 cAMP signalling is differentially modulated by single and double GLP1R coding variants seen in human populations, with implications for GLP‐1R agonist pharmacogenomics. Conclusions: Completely abolishing β‐arrestin recruitment improves the anti‐hyperglycaemic effects of GLP‐1R agonists in mice.
- 5 October 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (1) , 65-77
Open AccessAbolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists
Aim: Earlier studies have shown that peptide glucagon‐like peptide‐1 receptor (GLP‐1R) agonists with reduced β‐arrestin recruitment show enhanced anti‐hyperglycaemic efficacy through avoidance of GLP‐1R desensitization. However, the ligand modifications needed to decrease β‐arrestin recruitment usually also reduces GLP‐1R affinity, therefore higher doses are needed. Here we aimed to develop new, long‐acting, G protein‐biased GLP‐1R agonists with acute signalling potency comparable with semaglutide, to provide insights into specific experimental and therapeutic scenarios. Materials and Methods: New GLP‐1R agonist peptides were assessed using a variety of in vitro and in vivo assays. Results: First, we show that very substantial reductions in β‐arrestin recruitment efficacy are required to realize fully the benefits of GLP‐1R agonism on blood glucose lowering in mice, with more moderate reductions being less effective. Secondly, our lead compound (SRB107) performs substantially better than semaglutide for effects on blood glucose and weight loss, which may be jointly attributable to its biased agonist action and protracted pharmacokinetics. Thirdly, we show that biased agonist‐specific GLP‐1R internalization profiles occur at clinically relevant pharmacological concentrations. Finally, we show that SRB107 cAMP signalling is differentially modulated by single and double GLP1R coding variants seen in human populations, with implications for GLP‐1R agonist pharmacogenomics. Conclusions: Completely abolishing β‐arrestin recruitment improves the anti‐hyperglycaemic effects of GLP‐1R agonists in mice.
- Open Access
- 30 August 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (2) , e767-e782
The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction
Context: The gut-derived peptide hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY) are regulators of energy intake and glucose homeostasis and are thought to contribute to the glucose-lowering effects of bariatric surgery.Objective: To establish the metabolomic effects of a combined infusion of GLP-1, OXM, and PYY (tripeptide GOP) in comparison to a placebo infusion, Roux-en-Y gastric bypass (RYGB) surgery, and a very low-calorie diet (VLCD).Design and Setting: Subanalysis of a single-blind, randomized, placebo-controlled study of GOP infusion (ClinicalTrials.gov NCT01945840), including VLCD and RYGB comparator groups.Patients and Interventions: Twenty-five obese patients with type 2 diabetes or prediabetes were randomly allocated to receive a 4-week subcutaneous infusion of GOP (n = 14) or 0.9% saline control (n = 11). An additional 22 patients followed a VLCD, and 21 underwent RYGB surgery.Main Outcome Measures: Plasma and urine samples collected at baseline and 4 weeks into each intervention were subjected to cross-platform metabolomic analysis, followed by unsupervised and supervised modeling approaches to identify similarities and differences between the effects of each intervention.Results: Aside from glucose, very few metabolites were affected by GOP, contrasting with major metabolomic changes seen with VLCD and RYGB.Conclusions: Treatment with GOP provides a powerful glucose-lowering effect but does not replicate the broader metabolomic changes seen with VLCD and RYGB. The contribution of these metabolomic changes to the clinical benefits of RYGB remains to be elucidated.
- 30 August 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (2) , e767-e782
Open AccessThe Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction
Context: The gut-derived peptide hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY) are regulators of energy intake and glucose homeostasis and are thought to contribute to the glucose-lowering effects of bariatric surgery.Objective: To establish the metabolomic effects of a combined infusion of GLP-1, OXM, and PYY (tripeptide GOP) in comparison to a placebo infusion, Roux-en-Y gastric bypass (RYGB) surgery, and a very low-calorie diet (VLCD).Design and Setting: Subanalysis of a single-blind, randomized, placebo-controlled study of GOP infusion (ClinicalTrials.gov NCT01945840), including VLCD and RYGB comparator groups.Patients and Interventions: Twenty-five obese patients with type 2 diabetes or prediabetes were randomly allocated to receive a 4-week subcutaneous infusion of GOP (n = 14) or 0.9% saline control (n = 11). An additional 22 patients followed a VLCD, and 21 underwent RYGB surgery.Main Outcome Measures: Plasma and urine samples collected at baseline and 4 weeks into each intervention were subjected to cross-platform metabolomic analysis, followed by unsupervised and supervised modeling approaches to identify similarities and differences between the effects of each intervention.Results: Aside from glucose, very few metabolites were affected by GOP, contrasting with major metabolomic changes seen with VLCD and RYGB.Conclusions: Treatment with GOP provides a powerful glucose-lowering effect but does not replicate the broader metabolomic changes seen with VLCD and RYGB. The contribution of these metabolomic changes to the clinical benefits of RYGB remains to be elucidated.
- Open Access
- 31 March 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (6) , 1899-1905
Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men
Context Glucagon increases energy expenditure; consequently, glucagon receptor agonists are in development for the treatment of obesity. Obesity negatively affects the reproductive axis, and hypogonadism itself can exacerbate weight gain. Therefore, knowledge of the effects of glucagon receptor agonism on reproductive hormones is important for developing therapeutics for obesity; but reports in the literature about the effects of glucagon receptor agonism on the reproductive axis are conflicting. Objective The objective of this work is to investigate the effect of glucagon administration on reproductive hormone secretion in healthy young men. Design A single-blinded, randomized, placebo-controlled crossover study was conducted. Setting The setting of this study was the Clinical Research Facility, Imperial College Healthcare NHS Trust. Participants Eighteen healthy eugonadal men (mean ± SEM: age 25.1 ± 1.0 years; body mass index 22.5 ± 0.4 kg/m2; testosterone 21.2 ± 1.2 nmol/L) participated in this study. Intervention An 8-hour intravenous infusion of 2 pmol/kg/min glucagon or rate-matched vehicle infusion was administered. Main Outcome Measures Luteinizing hormone (LH) pulsatility; LH, follicle-stimulating hormone (FSH), and testosterone levels were measured. Results Although glucagon administration induced metabolic effects (insulin area under the curve: vehicle 1065 ± 292 min.µU/mL vs glucagon 2098 ± 358 min.µU/mL, P < .001), it did not affect LH pulsatility (number of LH pulses/500 min: vehicle 4.7 ± 0.4, glucagon 4.2 ± 0.4, P = .22). Additionally, there were no significant differences in circulating LH, FSH, or testosterone levels during glucagon administration compared with vehicle administration. Conclusions Acute administration of a metabolically active dose of glucagon does not alter reproductive hormone secretion in healthy men. These data are important for the continued development of glucagon-based treatments for obesity.
- 31 March 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (6) , 1899-1905
Open AccessAcute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men
Context Glucagon increases energy expenditure; consequently, glucagon receptor agonists are in development for the treatment of obesity. Obesity negatively affects the reproductive axis, and hypogonadism itself can exacerbate weight gain. Therefore, knowledge of the effects of glucagon receptor agonism on reproductive hormones is important for developing therapeutics for obesity; but reports in the literature about the effects of glucagon receptor agonism on the reproductive axis are conflicting. Objective The objective of this work is to investigate the effect of glucagon administration on reproductive hormone secretion in healthy young men. Design A single-blinded, randomized, placebo-controlled crossover study was conducted. Setting The setting of this study was the Clinical Research Facility, Imperial College Healthcare NHS Trust. Participants Eighteen healthy eugonadal men (mean ± SEM: age 25.1 ± 1.0 years; body mass index 22.5 ± 0.4 kg/m2; testosterone 21.2 ± 1.2 nmol/L) participated in this study. Intervention An 8-hour intravenous infusion of 2 pmol/kg/min glucagon or rate-matched vehicle infusion was administered. Main Outcome Measures Luteinizing hormone (LH) pulsatility; LH, follicle-stimulating hormone (FSH), and testosterone levels were measured. Results Although glucagon administration induced metabolic effects (insulin area under the curve: vehicle 1065 ± 292 min.µU/mL vs glucagon 2098 ± 358 min.µU/mL, P < .001), it did not affect LH pulsatility (number of LH pulses/500 min: vehicle 4.7 ± 0.4, glucagon 4.2 ± 0.4, P = .22). Additionally, there were no significant differences in circulating LH, FSH, or testosterone levels during glucagon administration compared with vehicle administration. Conclusions Acute administration of a metabolically active dose of glucagon does not alter reproductive hormone secretion in healthy men. These data are important for the continued development of glucagon-based treatments for obesity.
- 1 February 2015
- Published by Elsevier in The Lancet
- Vol. 385, S28
Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3–36 and its analogues in vivo
- 1 February 2015
- Published by Elsevier in The Lancet
- Vol. 385, S28
Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3–36 and its analogues in vivo
- Open Access
- 1 January 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 193 (1) , 69-76
Learning curve of vessel cannulation in rats using cumulative sum analysis
- 1 January 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 193 (1) , 69-76
Open AccessLearning curve of vessel cannulation in rats using cumulative sum analysis
- Open Access
- 15 December 2014
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 29 (2) , 171-181
Identification of plasma protease derived metabolites of glucagon and their formation under typical laboratory sample handling conditions
RATIONALE: Glucagon modulates glucose production, and it is also a biomarker for several pathologies. It is known to be unstable in human plasma, and consequently stabilisers are often added to samples, although these are not particularly effective. Despite this, there have not been any studies to identify in vitro plasma protease derived metabolites; such a study is described here. Knowledge of metabolism should allow the development of more effective sample stabilisation strategies. METHODS: Several novel metabolites resulting from the incubation of glucagon in human plasma were identified using high‐resolution mass spectrometry with positive electrospray ionisation. Tandem mass spectrometric (MS/MS) scans were acquired for additional confirmation using a QTRAP. Separation was performed using reversed‐phase ultra‐high‐performance liquid chromatography. The formation of these metabolites was investigated during a time‐course experiment and under specific stress conditions representative of typical laboratory handling conditions. Clinical samples were also screened for metabolites. RESULTS: Glucagon 3‐29 and [pGlu] 3 glucagon 3‐29 were the major metabolites detected, both of which were also present in clinical samples. We also identified two oxidised forms of [pGlu] 3 glucagon 3‐29 as well as glucagon 19‐29 , or 'miniglucagon', along with the novel metabolites glucagon 20‐29 and glucagon 21‐29 . The relative levels of these metabolites varied throughout the time‐course experiment, and under the application of the different sample handling conditions. Aprotinin stabilisation of samples had negligible effect on metabolite formation. CONCLUSIONS: Novel plasma protease metabolites of glucagon have been confirmed, and their formation characterised over a time‐course experiment and under typical laboratory handling conditions. These metabolites could be monitored to assess the effectiveness of new sample stabilisation strategies, and further investigations into their formation could suggest specific enzyme inhibitors to use to increase sample stability. In addition the potential of the metabolites to affect immunochemistry‐based assays as a result of cross‐reactivity could be investigated. Copyright © 2014 John Wiley & Sons, Ltd.
- 15 December 2014
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 29 (2) , 171-181
Open AccessIdentification of plasma protease derived metabolites of glucagon and their formation under typical laboratory sample handling conditions
RATIONALE: Glucagon modulates glucose production, and it is also a biomarker for several pathologies. It is known to be unstable in human plasma, and consequently stabilisers are often added to samples, although these are not particularly effective. Despite this, there have not been any studies to identify in vitro plasma protease derived metabolites; such a study is described here. Knowledge of metabolism should allow the development of more effective sample stabilisation strategies. METHODS: Several novel metabolites resulting from the incubation of glucagon in human plasma were identified using high‐resolution mass spectrometry with positive electrospray ionisation. Tandem mass spectrometric (MS/MS) scans were acquired for additional confirmation using a QTRAP. Separation was performed using reversed‐phase ultra‐high‐performance liquid chromatography. The formation of these metabolites was investigated during a time‐course experiment and under specific stress conditions representative of typical laboratory handling conditions. Clinical samples were also screened for metabolites. RESULTS: Glucagon 3‐29 and [pGlu] 3 glucagon 3‐29 were the major metabolites detected, both of which were also present in clinical samples. We also identified two oxidised forms of [pGlu] 3 glucagon 3‐29 as well as glucagon 19‐29 , or 'miniglucagon', along with the novel metabolites glucagon 20‐29 and glucagon 21‐29 . The relative levels of these metabolites varied throughout the time‐course experiment, and under the application of the different sample handling conditions. Aprotinin stabilisation of samples had negligible effect on metabolite formation. CONCLUSIONS: Novel plasma protease metabolites of glucagon have been confirmed, and their formation characterised over a time‐course experiment and under typical laboratory handling conditions. These metabolites could be monitored to assess the effectiveness of new sample stabilisation strategies, and further investigations into their formation could suggest specific enzyme inhibitors to use to increase sample stability. In addition the potential of the metabolites to affect immunochemistry‐based assays as a result of cross‐reactivity could be investigated. Copyright © 2014 John Wiley & Sons, Ltd.
- Open Access
- 1 December 2014
- Published by Future Science Ltd in Bioanalysis
- Vol. 6 (24) , 3295-3309
Development of a high-throughput UHPLC–MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma
Background: Published LC–MS/MS methods are not sensitive enough to quantify endogenous levels of glucagon. Results: An ultra high performance liquid chromatography-MS/MS (SRM) method for the quantitation of endogenous levels glucagon was successfully developed and qualified. A novel 2D extraction procedure was used to reduce matrix suppression, background noise and interferences. Glucagon levels in samples from healthy volunteers were found to agree with radioimmunoassay (RIA) derived literature values. Bland–Altman analysis showed a concentration-dependent positive bias of the LC/MS–MS assay versus an RIA. Both assays produced similar pharmacokinetic profiles, both of which were feasible considering the nature of the study. Conclusion: Our method is the first peer reviewed LC–MS/MS method for the quantitation of endogenous levels of glucagon, and offers a viable alternative to RIA-based approaches.
- 1 December 2014
- Published by Future Science Ltd in Bioanalysis
- Vol. 6 (24) , 3295-3309
Open AccessDevelopment of a high-throughput UHPLC–MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma
Background: Published LC–MS/MS methods are not sensitive enough to quantify endogenous levels of glucagon. Results: An ultra high performance liquid chromatography-MS/MS (SRM) method for the quantitation of endogenous levels glucagon was successfully developed and qualified. A novel 2D extraction procedure was used to reduce matrix suppression, background noise and interferences. Glucagon levels in samples from healthy volunteers were found to agree with radioimmunoassay (RIA) derived literature values. Bland–Altman analysis showed a concentration-dependent positive bias of the LC/MS–MS assay versus an RIA. Both assays produced similar pharmacokinetic profiles, both of which were feasible considering the nature of the study. Conclusion: Our method is the first peer reviewed LC–MS/MS method for the quantitation of endogenous levels of glucagon, and offers a viable alternative to RIA-based approaches.
- Open Access
- 1 November 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (11) , E2317-E2324
Combination of Peptide YY3–36with GLP-17–36 amideCauses an Increase in First-Phase Insulin Secretion after IV Glucose
Context: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY3–36 and GLP-17–36 amide, on glucose homeostasis are unknown. Objective: This study sought to investigate the acute effects of PYY3–36 and GLP-17–36 amide, individually and in combination, on insulin secretion and sensitivity. Setting and Design: Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY3–36 alone, GLP-17–36 amide alone, and a combination of PYY3–36 and GLP-17–36 amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. Results: PYY3–36 alone caused a small but nonsignificant increase in AIRg. GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. Conclusions: PYY3–36 lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY3–36 and GLP-17–36 amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.
- 1 November 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (11) , E2317-E2324
Open AccessCombination of Peptide YY3–36with GLP-17–36 amideCauses an Increase in First-Phase Insulin Secretion after IV Glucose
Context: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY3–36 and GLP-17–36 amide, on glucose homeostasis are unknown. Objective: This study sought to investigate the acute effects of PYY3–36 and GLP-17–36 amide, individually and in combination, on insulin secretion and sensitivity. Setting and Design: Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY3–36 alone, GLP-17–36 amide alone, and a combination of PYY3–36 and GLP-17–36 amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. Results: PYY3–36 alone caused a small but nonsignificant increase in AIRg. GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. Conclusions: PYY3–36 lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY3–36 and GLP-17–36 amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.
- Open Access
- 13 October 2014
- Published by American Diabetes Association in Diabetes
- Vol. 63 (11) , 3711-3720
Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
Obesity is a growing epidemic, and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs that aim to cause effective weight loss with minimal side effects. Both glucagon and GLP-1 reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. We hypothesized that the combination of both peptides, administered at doses that are individually subanorectic, would reduce appetite, while GLP-1 would protect against the hyperglycemic effect of glucagon. In this double-blind crossover study, subanorectic doses of each peptide alone, both peptides in combination, or placebo was infused into 13 human volunteers for 120 min. An ad libitum meal was provided after 90 min, and calorie intake determined. Resting energy expenditure was measured by indirect calorimetry at baseline and during infusion. Glucagon or GLP-1, given individually at subanorectic doses, did not significantly reduce food intake. Coinfusion at the same doses led to a significant reduction in food intake of 13%. Furthermore, the addition of GLP-1 protected against glucagon-induced hyperglycemia, and an increase in energy expenditure of 53 kcal/day was seen on coinfusion. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and diabetes.
- 13 October 2014
- Published by American Diabetes Association in Diabetes
- Vol. 63 (11) , 3711-3720
Open AccessCoinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
Obesity is a growing epidemic, and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs that aim to cause effective weight loss with minimal side effects. Both glucagon and GLP-1 reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. We hypothesized that the combination of both peptides, administered at doses that are individually subanorectic, would reduce appetite, while GLP-1 would protect against the hyperglycemic effect of glucagon. In this double-blind crossover study, subanorectic doses of each peptide alone, both peptides in combination, or placebo was infused into 13 human volunteers for 120 min. An ad libitum meal was provided after 90 min, and calorie intake determined. Resting energy expenditure was measured by indirect calorimetry at baseline and during infusion. Glucagon or GLP-1, given individually at subanorectic doses, did not significantly reduce food intake. Coinfusion at the same doses led to a significant reduction in food intake of 13%. Furthermore, the addition of GLP-1 protected against glucagon-induced hyperglycemia, and an increase in energy expenditure of 53 kcal/day was seen on coinfusion. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and diabetes.